A delegation of executives from the pharmaceutical company Ferrer met on March 3 with the senior management of VHIR to explore future collaboration between the two entities. During the meeting, which took place at the headquarters of VHIR, Ferrer presented its interests and its various subsidiaries, in research, innovation and development. VHIR showed its skills as an institute, as well as the potential of their research groups.From Ferrer presented their strategies: Olga Fidalgo, Corporate Director Business Development & Collaborative Research, Andrés Fernández, Head of Advanced Biotherapeutics, Ricardo Palacios, General Director of Diater Laboratories, Mona Johansson, Head of Project & Alliance Development, Luis Ruiz-ávila CEO of Spherium Biomed and Manuel Martínez, CEO of Gendiag. Representing VHIR there were its director, Joan Comella, the Deputy Director, Fátima Núñez, the Director of the Department of Business Development, Laia Arnal, and the Director of Scientific and Technical Services, Xavier Cañas.Ferrer explained his strategy in recent years, dedicated to expand and diversify its research and innovation. Their representatives highlighted the areas in which they work the most and the ones in which there can be set up a relationship with VHIR, such as antibiotic resistance, design of medical devices, immunology, acceleration of projects and kits for genetic prediction.The next step is to look for the specific research groups that could work with each of the Ferrer's divisions to carry out individual projects.